Arestat™ comprises two fundamentally different aspects of
our platform stabilization technology. Both utilize excipients
and buffers approved by the FDA and EMEA in an unconventional
manner to achieve the desired stability.
Both platform technologies are available for licensing for applications involving
therapeutic proteins, vaccines, medical devices and diagnostics.
Published papers and posters available for downloading
are shown in table below.
| Papers / Posters | Date Published | Location | |
|---|
| BioProcess International | 23/09/2008 | Anaheim, CA, USA |  |